OptiNose Inc
NASDAQ:OPTN

Watchlist Manager
OptiNose Inc Logo
OptiNose Inc
NASDAQ:OPTN
Watchlist
Price: 9.6 USD -1.13% Market Closed
Market Cap: 97.2m USD

OptiNose Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OptiNose Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
OptiNose Inc
NASDAQ:OPTN
Free Cash Flow
-$44.8m
CAGR 3-Years
17%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Free Cash Flow
$19.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Free Cash Flow
$15.3B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
31%
Pfizer Inc
NYSE:PFE
Free Cash Flow
$10.4B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Free Cash Flow
$13B
CAGR 3-Years
-5%
CAGR 5-Years
14%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Free Cash Flow
$6.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
No Stocks Found

OptiNose Inc
Glance View

Market Cap
96.6m USD
Industry
Pharmaceuticals

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

OPTN Intrinsic Value
14.52 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is OptiNose Inc's Free Cash Flow?
Free Cash Flow
-44.8m USD

Based on the financial report for Dec 31, 2024, OptiNose Inc's Free Cash Flow amounts to -44.8m USD.

What is OptiNose Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
13%

Over the last year, the Free Cash Flow growth was -115%. The average annual Free Cash Flow growth rates for OptiNose Inc have been 17% over the past three years , 13% over the past five years .

Back to Top